Skip to main contentAll experts

Kyle Ruffing

CLIN AST PROF

MD-NEUROLOGY

  • CLIN AST PROF
    MD-NEUROLOGY

GRANTS

  • GRANT
    An Open-Label Extension Study to Assess the Long-term Effect of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy
    Edgewise Therapeutics31 Mar 2025 - 30 Mar 2030
    Active
  • GRANT
    214 CTOA: Ruffing
    University of Florida9 May 2024 - 20 Aug 2029
    Active
  • GRANT
    Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy
    Edgewise Therapeutics21 Aug 2023 - 20 Aug 2028
    Active